NCT07650448尚未招募不适用
WATER IV Prostate Cancer: Aquablation Versus Active Surveillance for the Treatment of Localized Prostate Cancer
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 333
- 试验地点
- 26
- 主要终点
- Freedom from GG ≥ 2
研究概览
简要总结
The WATER IV study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with localized prostate cancer.
详细描述
The WATER IV AS sub-study is a multicenter, prospective, randomized clinical trial that aims to evaluate the safety and efficacy of Aquablation therapy in men with low to intermediate risk localized prostate cancer who are candidates for active surveillance. Participants will be randomized to either Aquablation Therapy or active surveillance and followed up to 10 years.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Biological male with age ≥ 45 years at the time of consent
- •Biopsy positive Grade Group 2 prostate cancer or biopsy positive Grade Group 1 MRI visible lesion (PI-RADS/Likert ≥ 3)
- •First prostate cancer diagnoses within 18 months (545 days) of consent
- •Are candidates for active surveillance
- •Clinical Stage ≤ T2c
- •PSA < 15 ng/ml
- •Prostate volume ≥25 ml
排除标准
- •Any prior or current local or systemic treatment for prostate cancer, including but not limited to surgery, radiation therapy (external or brachytherapy), tissue ablation, hormone therapy or chemotherapy.
- •Patients with previous surgical or minimally invasive treatment of benign prostatic hyperplasia within the prior 3 months of study treatment.
- •Evidence of lymph node, bone metastasis, extracapsular extension or seminal vesicle invasion.
- •Patient is unwilling to accept a blood transfusion if required.
- •Any condition or history of illness or surgery that may pose an additional risk to patients undergoing the Aquablation or radical prostatectomy procedure such as:
- •5a. Medical conditions that preclude the use of anesthesia; 5b. Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of rectal injury (i.e. fistula formation); 5c. Patient is unable to stop anticoagulants or antiplatelet agents prior to study treatment per standard of care; 5d. Any other condition or history of infection, illness or surgery that in the opinion of the investigator might affect the outcome of the study procedure, study conduct, and study results; or pose additional risks to the patient (e.g., other cancer, active urethral stricture disease).
- •6. Patients who are unable to provide informed consent due to cognitive impairment, legal status (such as incarceration), or other factors limiting autonomy or unwilling or unable to follow study instructions including randomization and complete all required study visits through 10 years. This includes individuals with severe cognitive disabilities, those under legal guardianship, or those currently incarcerated.
- •7. Patient currently participating in other studies unless approved by Sponsor in writing.
- •8. More than one complete biopsy beyond the diagnostic biopsy comprising both a systematic biopsy and biopsy of any MRI visible lesion (PI-RADS/Likert ≥ 3).
- •9. GG2 disease with PSA ≥ 10 OR stage ≥ T2b OR ≥ 50% of biopsy cores positive (multiple cores taken from any MRI visible lesion are counted as one continuous core).
研究组 & 干预措施
Aquablation Therapy
Experimental
The Aquablation Therapy arm will receive Aquablation with either the AQUABEAM Robotic System or HYDROS Robotic System
干预措施: Aquablation Therapy (Device)
Active Surveillance
Active Comparator
The active surveillance arm will receive standard-of-care for prostate cancer management.
干预措施: Active Surveillance (Other)
结局指标
主要结局
Freedom from GG ≥ 2
时间窗: 12 Months
次要结局
- Freedom from persistent or increased MRI suspicion AND additional prostate cancer treatment(3 Years)
研究者
研究点 (26)
Loading locations...
相似试验
尚未招募
4 期
To assess safety and efficacy of Relugolix Tablets in treating Advanced Prostate CancerCTRI/2025/02/080273Sun Pharmaceutical Industries Limited (SPIL)127
招募中
不适用
Water Vapor Ablation for Prostate Cancer: Long-Term RegistryProstate CancerNCT07455058Francis Medical Inc.2,500
尚未招募
不适用
Scientific data review of prostate cancer patients to study treatment patterns and understand need gaps.CTRI/2024/08/072504Pfizer Limited950
招募中
不适用
CUIMC Focal Therapy RegistryProstate CancerNCT07623941Columbia University1,000
招募中
不适用
Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With AcupunctureProstatic NeoplasmsNCT07335224Inova Health Care Services24